The global radiopharmaceuticals market size reached US$ 5.2 Billion in 2022. Looking forward, the publisher expects the market to reach US$ 7.3 Billion by 2028, exhibiting a growth rate (CAGR) of 5.8% during 2022-2028.
Radiopharmaceuticals are unique formulations comprising radioisotopes that are used in clinical areas for diagnosis and therapy. These medicinal drugs are administered by a radio pharmacist, a medical professional who specializes in nuclear medicine. They are taken in the form of a pill or injected into a vein or cavity of the patient’s body. Once they reach the targeted location, they release radioactive agents to destroy the tumor cells. As a result, radiopharmaceuticals are used to treat thyroid, brain, lymphoma and other types of cancer that have spread to the bones.
2. What is the expected growth rate of the global radiopharmaceuticals market during 2023-2028?
3. What has been the impact of COVID-19 on the global radiopharmaceuticals market?
4. What are the key factors driving the global radiopharmaceuticals market?
5. What is the breakup of the global radiopharmaceuticals market based on the product type?
6. What is the breakup of the global radiopharmaceuticals market based on the application?
7. What is the breakup of the global radiopharmaceuticals market based on the end use?
8. What are the key regions in the global radiopharmaceuticals market?
9. Who are the key players/companies in the global radiopharmaceuticals market?
Radiopharmaceuticals are unique formulations comprising radioisotopes that are used in clinical areas for diagnosis and therapy. These medicinal drugs are administered by a radio pharmacist, a medical professional who specializes in nuclear medicine. They are taken in the form of a pill or injected into a vein or cavity of the patient’s body. Once they reach the targeted location, they release radioactive agents to destroy the tumor cells. As a result, radiopharmaceuticals are used to treat thyroid, brain, lymphoma and other types of cancer that have spread to the bones.
Radiopharmaceuticals Market Trends:
The increasing prevalence of cancerous diseases on account of the rising aging population and unhealthy dietary patterns represent the key factors contributing to the growing use of radiopharmaceuticals across the globe. Apart from this, the escalating number of diagnostic centers is also supporting the market. Moreover, the rising number of oncologists that are suggesting disease-targeted cancer therapy, which utilizes drugs to target specific proteins and genes involved in the development of cancer cells, are positively influencing the overall sales. Furthermore, the use of radiolabeled peptides and monoclonal antibodies for the diagnosis and treatment of cancerous tumors, along with rising healthcare expenditures, is strengthening the market growth. Other major factors anticipated to propel the growth of the market include the increasing use of radiopharmaceuticals by oncologists to track radioactivity throughout the body and determine the presence of cancer cells and the increasing shift towards positron emission tomography (PET) and single-photon emission computerized tomography (SPECT) scans.Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global radiopharmaceuticals market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product type, application and end use.Breakup by Product Type:
- Diagnostic Nuclear Medicine
- Therapeutic Nuclear Medicine
Breakup by Application:
- Oncology
- Cardiology
- Neurology
- Endocrinology
- Others
Breakup by End Use:
- Hospitals and Clinics
- Research Institutes
- Diagnostic Centers
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Advanced Accelerator Applications (Novartis AG), Bayer AG, Bracco S.p.A., Cardinal Health Inc., Curium Pharma, General Electric Company, IBA RadioPharma Solutions, Jubilant Pharma Limited, Lantheus Medical Imaging Inc, Nordion Inc. (Sotera Health), NTP Radioisotopes SOC Ltd, PharmaLogic Holdings Corp. and Siemens AG.Key Questions Answered in This Report
1. What was the size of the global radiopharmaceuticals market in 2022?2. What is the expected growth rate of the global radiopharmaceuticals market during 2023-2028?
3. What has been the impact of COVID-19 on the global radiopharmaceuticals market?
4. What are the key factors driving the global radiopharmaceuticals market?
5. What is the breakup of the global radiopharmaceuticals market based on the product type?
6. What is the breakup of the global radiopharmaceuticals market based on the application?
7. What is the breakup of the global radiopharmaceuticals market based on the end use?
8. What are the key regions in the global radiopharmaceuticals market?
9. Who are the key players/companies in the global radiopharmaceuticals market?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Radiopharmaceuticals Market
6 Market Breakup by Product Type
7 Market Breakup by Application
8 Market Breakup by End Use
9 Market Breakup by Region
10 SWOT Analysis
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Advanced Accelerator Applications (Novartis AG)
- Bayer AG
- Bracco S.p.A.
- Cardinal Health Inc.
- Curium Pharma
- General Electric Company
- IBA RadioPharma Solutions
- Jubilant Pharma Limited
- Lantheus Medical Imaging Inc
- Nordion Inc. (Sotera Health)
- NTP Radioisotopes SOC Ltd
- PharmaLogic Holdings Corp. and Siemens AG
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 140 |
| Published | November 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 5.2 Billion |
| Forecasted Market Value ( USD | $ 7.3 Billion |
| Compound Annual Growth Rate | 5.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
